UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 15, 2010
ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)
Massachusetts |
| 0-17999 |
| 04-2726691 |
(State or other |
| (Commission File |
| (IRS Employer |
830 Winter Street, Waltham, MA 02451
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (781) 895-0600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 – DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS
(a) – (d) Not applicable.
(e) On June 15, 2010, the Compensation Committee of the Board of Directors of ImmunoGen, Inc. (the “Company”) increased the target bonus for Mr. Daniel M. Junius, the Company’s President and Chief Executive Officer, under the Company’s annual executive bonus program from 45% to 50% of his annual base salary, beginning with the Company’s fiscal year 2011 starting on July 1, 2010. The Committee also determined to leave the target bonuses for the Company’s other executive officers unchanged from the previous year.
(f) Not applicable
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ImmunoGen, Inc. |
| (Registrant) |
|
|
Date: June 30, 2010 | /s/ Gregory D. Perry |
|
|
| Gregory D. Perry |
| Senior Vice President and Chief Financial Officer |